JERSEY CITY, N.J., Sept. 13 /PRNewswire/ -- Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, today announced it has entered into an exclusive license agreement with Rutgers, The State University of New Jersey, to access their polyarylate patent estate. Lux expects to work in partnership with Rutgers to leverage the assets for the treatment of eye diseases affecting the ocular surface or the back of the eye. Potential therapeutic benefits include sustained therapeutic drug levels at or near the site of the disease, resulting potentially in superior efficacy, while limiting systemic exposure to the drug thus potentially minimizing side effects. Additional advantages include continuous drug delivery over long periods of time, increasing patient convenience and compliance. Financial terms of the agreement were not disclosed.
